TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04036422

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rejoyce (Rehabilitation Joystick for Computerized Exercise)
Description: Rejoyce (Rehabilitation Joystick for Computerized Exercise), is a computer game based task specific exercise system developed by Rehabtronics Inc. for use as part of the treatment of stroke and spinal cord injury patients. Rejoyce aims to improve upper extremity and hand function by encouraging neuroplasticity through repeated task specific games.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rejoyce (Rehabilitation Joystick for Computerized Exercise)
Description: Rejoyce (Rehabilitation Joystick for Computerized Exercise), is a computer game based task specific exercise system developed by Rehabtronics Inc. for use as part of the treatment of stroke and spinal cord injury patients. Rejoyce aims to improve upper extremity and hand function by encouraging neuroplasticity through repeated task specific games.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy
Description: A physical therapy session customised to the patient's needs overseen by a physical medicine and rehabilitation specialist and conducted by a physiotherapist which includes range of motion, neurophysiological and strengthening exercises, balance and coordination training and walking exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: A physical therapy session customised to the patient's needs overseen by a physical medicine and rehabilitation specialist and conducted by a physiotherapist which includes range of motion, neurophysiological and strengthening exercises, balance and coordination training and walking exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational therapy
Description: Task based exercises overseen by a physical medicine and rehabilitation specialist and conducted by an occupational therapist aimed at improving upper arm dexterity, coordination and strength.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occupational therapy
Description: Task based exercises overseen by a physical medicine and rehabilitation specialist and conducted by an occupational therapist aimed at improving upper arm dexterity, coordination and strength.
Study: NCT02059070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Post-operative epidural 0.125% Ropivacaine Interscalene brachial plexus block, 20-28 hrs post surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Post-operative epidural 0.125% Bupivacaine Interscalene brachial plexus block, 20-28 hrs post surgery.
Study: NCT01944930

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laparoscopic narrow band imaging

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laparoscopic narrow band imaging

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard white-light laparoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard white-light laparoscopy
Study: NCT00394810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panzem® NCD
Description: suspension, 100 mg/mL, four times daily continuous dosing
Study: NCT04582318

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM621
Description: NGM621 will be administered via IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM621
Description: NGM621 will be administered via IV infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NGM621
Description: NGM621 will be administered via IV infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NGM621
Description: NGM621 will be administered via IV infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered via IV infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered via IV infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered via IV infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered via IV infusion
Study: NCT03515967

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-PAS Goggles
Description: Portable, head-mounted display goggle system with integrated eye capture technology

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-PAS Goggles
Description: Portable, head-mounted display goggle system with integrated eye capture technology
Study: NCT02062580

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: BCG
Study: NCT04249271

Intervention type: OTHER
Intervention: serum sampling
Description: repeated serum sampling during pregnancy and thereafter

Intervention type: OTHER
Intervention: serum sampling
Description: repeated serum sampling during pregnancy and thereafter

Intervention type: OTHER
Intervention: serum sampling
Description: repeated serum sampling during pregnancy and thereafter

Intervention type: OTHER
Intervention: serum sampling
Description: repeated serum sampling during pregnancy and thereafter

Intervention type: OTHER
Intervention: serum sampling
Description: repeated serum sampling during pregnancy and thereafter

Intervention type: OTHER
Intervention: serum sampling
Description: repeated serum sampling during pregnancy and thereafter
Study: NCT00800137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low molecular weight heparin or unfractionated heparin
Description: For elective patients with greater than 5 days pre-implant; discontinue oral anti-coagulation (coumadin) 5 days before the procedure. Full therapeutic doses of subcutaneous LMWH 3 days before the procedure.~Patients with less than 5 days to implant can be given vitamin K (up to 2 mg) at the investigator discretion and start full therapeutic doses of either subcutaneous LMWH or IV Unfractionated Heparin (choice is at investigator's discretion) when INR is below the upper limit of the prescribed therapeutic range for the patient (usually greater than or equal to 2; 2.5 for some valve patients) and surgery to proceed when INR is less than 1.6.~Last dose given in the morning(ie. \> 24 hours)of the day prior to the procedure.~Oral anti-coagulation (coumadin) will be resumed on the evening of the procedure.~Full dose LMWH or full dose IV heparin will be restarted 24 hours after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin or coumadin
Description: Continue on oral anti-coagulant (coumadin). INR on the day of surgery will be \< 3.0
Study: NCT03380377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazakizumab
Description: Clazakizumab 25 mg subcutaneous monthly x 6 doses (or max of 12 doses) will be given to patients who are enrolled in this clinical trial.
Study: NCT00176306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg IV
Description: PK in obesity
Study: NCT00045942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PKC412
Description: PKC412 was supplied as soft gelatin capsules containing 25 mg PKC412.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PKC412
Description: PKC412 was supplied as soft gelatin capsules containing 25 mg PKC412.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PKC412
Description: PKC412 was supplied as soft gelatin capsules containing 25 mg PKC412.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PKC412
Description: PKC412 was supplied as soft gelatin capsules containing 25 mg PKC412.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PKC412
Description: PKC412 was supplied as soft gelatin capsules containing 25 mg PKC412.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PKC412
Description: PKC412 was supplied as soft gelatin capsules containing 25 mg PKC412.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PKC412
Description: PKC412 was supplied as soft gelatin capsules containing 25 mg PKC412.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PKC412
Description: PKC412 was supplied as soft gelatin capsules containing 25 mg PKC412.
Study: NCT02331095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin belongs to the statin class of drugs, and is routinely used for prevention of cardiovascular diseases and/or reduction of cholesterol levels. It has been shown to decrease the risk of first venous thromboembolism in an otherwise healthy population with elevated high-sensitivity C-reactive protein (hs-CRP).
Study: NCT02297932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Participants will engage in a home-based strength training program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Participants will engage in a home-based stretching training program
Study: NCT02331095

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulation Therapy
Description: Warfarin is a standard anticoagulation in the treatment for venous thromboembolism. The dose will be adjusted to goal INR of 2-3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulation Therapy
Description: Warfarin is a standard anticoagulation in the treatment for venous thromboembolism. The dose will be adjusted to goal INR of 2-3.
Study: NCT02618213

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optiflow Junior
Description: Humified air are dispensed through the system. Airflow, FiO2 (Fraction of inspired oxygen) , SpO2 (peripheral capillary Oxygen saturation) and respiratory rate are noted each hour. Progression of condition might lead to change of system og mechanical ventilation. poor tolerance might lead to change of system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continous Positive Airway Pressure
Description: Humified air are dispensed throug the system. Airflow, FiO2, SpO2 and respiratory rate are noted each hour. Progression of condition might lead to change of system or mechanical ventilation. Poor tolerance might lead to change of system.
Study: NCT02266953

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of communication tool about diet
Description: The experimental intervention comprise the public health nurse's use of an image based communication tool in her dialogue with the family. This is in order to act in a patient centered way to facilitate participation by the parents and focus on relevant food and feeding practices from the parents' point of view.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: The public health nurses at child health centres in control municipalities are performing consultations at the child health centres as usual and without using the particular communication tool about diet.
Study: NCT04896450

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Guided tissue regeneration (GTR)
Description: GTR is handled with the utilization of a coronally advanced flap, followed by a thorough debridement of the denudated root surface and the intrabony component. Regenerative materials are resorbable collagen membrane (BioGide, Geistlich Phara AG, Wolhusen, Switzerland) and deproteinized bovine bone mineral (BioOss, Geistlich Phara AG), finally surgery is finished with multilayer suturing technique.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR)
Description: GTR is handled with the utilization of a coronally advanced flap, followed by a thorough debridement of the denudated root surface and the intrabony component. Regenerative materials are resorbable collagen membrane (BioGide, Geistlich Phara AG, Wolhusen, Switzerland) and deproteinized bovine bone mineral (BioOss, Geistlich Phara AG), finally surgery is finished with multilayer suturing technique.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthodontic tooth movement (OTM)
Description: An early initialization of the tooth movement with the help of a multibond fixed orthodontic device utilizing low level of continuous orthodontic forces.
Study: NCT03741387

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gain-frame questionnaire
Description: Questionnaires focusing on the attitude of saving patients' lives were given to Rh negative blood donors in this group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Loss-frame questionnaire
Description: Questionnaires focusing on the attitude of preventing patients from death were given to Rh negative blood donors in this group.
Study: NCT01944280

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage
Study: NCT03748615

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer Guided ridge splitting in posterior mandible
Description: The computer guided ridge splitting for patients with atrophic posterior mandible and with residual bone width at least 3 to 5mm of residual ridge.~The selected patients will be informed of the nature of the research work and informed consent will be signed.~Radiographic examination included preoperative digital panoramic radiograph with 1:1 magnification for each patient as a primary survey to obtain an approximation of the available bone height and detect the presence of remaining roots and localized pathosis.~Computer surgical guides are fabricated for partially edentulous patients using teeth and tissue as support for the guide.~The same surgeon performed all surgeries. All surgical procedures were performed under strict aseptic conditions, all patients received nerve block local anesthesia (Articaine 4% 1:100 000 epinephrine).~A crestal incision is made using No. 15 blade extending over the posterior mandible using computer guided surgical stent.~no flap elevation .
Study: NCT03871491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: The study intervention is a single 2 g dose of directly observed oral azithromycin, to be administered as four 500 mg pills or tablets directly after randomization. By random allocation, participants will receive 2 g of oral azithromycin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical appearing placebo, administered as a single oral dose directly after randomization.
Study: NCT00656890

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: sterile saline for injection
Description: 10mg/kg/dose sterile saline injected every other week for a total of 4 doses
Study: NCT01199848

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: whole milk shake without strawberry powder served with the high fat/carbohydrate test meal
Study: NCT03640780

Intervention type: OTHER
Intervention: observation
Description: The surgical ages and other information between two groups were compared.

Intervention type: OTHER
Intervention: observation
Description: The surgical ages and other information between two groups were compared.
Study: NCT00885820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Oral
Study: NCT00656890

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MDX-1100
Description: 10mg/kg/dose MDX-1100 injected every other week for a total of 4 doses
Study: NCT03843047

Intervention type: DRUG
Group type: OTHER
Intervention: 3 mg/mL nicotine strength e-liquid
Description: Availability of 3 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace

Intervention type: DRUG
Group type: OTHER
Intervention: 3 mg/mL nicotine strength e-liquid
Description: Availability of 3 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace

Intervention type: DRUG
Group type: OTHER
Intervention: 6 mg/mL nicotine strength e-liquid
Description: Availability of 6 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace

Intervention type: DRUG
Group type: OTHER
Intervention: 6 mg/mL nicotine strength e-liquid
Description: Availability of 6 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace

Intervention type: DRUG
Group type: OTHER
Intervention: 12 mg/mL nicotine strength e-liquid
Description: Availability of 12 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace

Intervention type: DRUG
Group type: OTHER
Intervention: 12 mg/mL nicotine strength e-liquid
Description: Availability of 12 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace

Intervention type: DRUG
Group type: OTHER
Intervention: 24 mg/mL nicotine strength e-liquid
Description: Availability of 24 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace

Intervention type: DRUG
Group type: OTHER
Intervention: 24 mg/mL nicotine strength e-liquid
Description: Availability of 24 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace
Study: NCT02229201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: 4-6 mg/kg/h during anaesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: 0.8 MAC
Study: NCT03772912

Intervention type: DEVICE
Intervention: HEMOBLAST Bellows
Description: The HEMOBLAST™ Bellows hemostatic agent consists of a bellows pre-loaded with 1.65g of powder composed of collagen, chondroitin sulfate, and thrombin (1500 IU). HEMOBLAST™ Bellows is indicated in surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical, except in neurosurgical, ophthalmic, and urological procedures.
Study: NCT03314805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astragalus polysaccharides 500 mg
Description: PG2 (500 mg in 500 ml saline), 3 days via i.v. infusion per chemotherapy cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 ml saline, 3 days via i.v. infusion per chemotherapy cycle

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: EC Chemotherapy
Description: Epirubicin plus Cyclophosphamide every 21 days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EC Chemotherapy
Description: Epirubicin plus Cyclophosphamide every 21 days
Study: NCT01639326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan high doses
Description: Irinotecan dose of 300 mg / m² in patients UGT1A1 \* 1 / \* 1 and 260 mg / m² in patients UGT1A1 \* 1 / \* 28 intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m² intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan standard doses
Description: Irinotecan at a dose of 180 mg / m² intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours.
Study: NCT01126580

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (oral)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (oral)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (subcutaneous)
Study: NCT01199848

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10G
Description: whole milk shake with 10g strawberry powder served with the high fat/carbohydrate test meal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 20G
Description: whole milk shake with 20 strawberry powder served with the high fat/carbohydrate test meal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 40G
Description: whole milk shake with 40g strawberry powder served with the high fat/carbohydrate test meal

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebonofiber
Description: Placebo without Fiber
Study: NCT02550899

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transanal submucosal injection group 1
Description: Transanal submucosal injection using an anoscope using four sites circumferentially above the dentate line at 12, 3, 6 and 9 o'clock using 4 ml polyacrylamide

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transanal submucosal injection group 2
Description: Transanal submucosal injection using an anoscope using three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 4 ml polyacrylamide

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transanal submucosal injection group 3
Description: Transanal submucosal injection using an anoscope using three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 6 ml polyacrylamide
Study: NCT03560973

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: ramucirumab/ placebo was added to gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: ramucirumab/ placebo was added to gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: ramucirumab/ placebo was added to gemcitabine
Study: NCT01917786

Intervention type: DEVICE
Intervention: ECG

Intervention type: DEVICE
Intervention: ECG
Study: NCT00803114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preservative-free epidural morphine
Description: One time dose of preservative-free epidural morphine 2.5 mg given within one hour following vaginal delivery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 ml of epidural preservative-free saline given within one hour following vaginal delivery
Study: NCT01053429

Intervention type: DRUG
Intervention: ziprasidone
Description: This is a non-interventional, pharmacovigilance study, therefore patients are on ziprasidone as prescribed by their doctor.
Study: NCT01708057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8683
Description: AZD8683 administered via inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8683
Description: AZD8683 administered via inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8683
Description: AZD8683 administered via inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8683
Description: AZD8683 administered via inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered via inhalation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium administered via inhalation
Study: NCT04423848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Hospital for Lymphoma
Description: Remote monitoring and home-based care designed for hospitalized patients with lymphoma
Study: NCT03563300

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wheat flour
Description: Wheat flour will be administered once daily for 7 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo will be administered blindly versus wheat flour for 7 days